Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
Chengming Liu, Sufei Zheng, Zhanyu Wang, et al.
Cancer Communications (2022) Vol. 42, Iss. 9, pp. 828-847
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
Kun Pang, Zhenduo Shi, Liuya Wei, et al.
Drug Resistance Updates (2022) Vol. 66, pp. 100907-100907
Closed Access | Times Cited: 113
Next batter up! Targeting cancers with KRAS-G12D mutations
Mara N. Zeissig, Lauren M. Ashwood, Olga Kondrashova, et al.
Trends in cancer (2023) Vol. 9, Iss. 11, pp. 955-967
Open Access | Times Cited: 43
Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24
The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
Qinglong Ma, Wenyang Zhang, Kongming Wu, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Sahar F. Bannoura, Husain Yar Khan, Asfar S. Azmi
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 61
KRAS in NSCLC: State of the Art and Future Perspectives
Priscilla Cascetta, Arianna Marinello, Chiara Lazzari, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5430-5430
Open Access | Times Cited: 43
KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration
Yunkai Yang, Huan Zhang, Shanshan Huang, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 2, pp. 709-709
Open Access | Times Cited: 27
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
Kexun Zhou, Shuo Li, Yi Zhao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
Alex Watterson, Matthew A. Coelho
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 23
Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors
Léa Berland, Zeina Gabr, Michelle Chang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
Impact of KRAS mutation on the tumor microenvironment in colorectal cancer
Yiru Zhou, Yeye Kuang, Chan Wang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 5, pp. 1947-1964
Open Access | Times Cited: 8
Harnessing phytochemicals: innovative strategies to enhance cancer immunotherapy
Qianru Zhu, Ruonan Zhang, Min Jin Ha, et al.
Drug Resistance Updates (2025) Vol. 79, pp. 101206-101206
Open Access | Times Cited: 1
Inflammation in cancer: therapeutic opportunities from new insights
Yifei Xie, Fangfang Liu, Yunfei Wu, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Flavonoids as potential KRAS inhibitors: DFT, molecular docking, molecular dynamics simulation and ADMET analyses
Prinsa Prinsa, Supriyo Saha, Md Z. H. Bulbul, et al.
Journal of Asian Natural Products Research (2024) Vol. 26, Iss. 8, pp. 955-992
Closed Access | Times Cited: 7
Serum KL-6 levels reflect the severity of interstitial lung disease caused by immune checkpoint inhibitors
Xiaoping Li, Dan Xue, Qiongying Wei, et al.
Immunobiology (2025) Vol. 230, Iss. 1, pp. 152866-152866
Open Access
Mechanisms and Strategies of Immunosenescence Effects on Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Analysis and Future Directions
Huatao Zhou, Zilong Zheng, Chengming Fan, et al.
Seminars in Cancer Biology (2025) Vol. 109, pp. 44-66
Closed Access
Identification of T cell dysfunction molecular subtypes and exploration of potential immunotherapy targets in BRAF V600E-mutant colorectal cancer
Ting Gu, Haonan Qi, Jiaqi Wang, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer
Han Wu, Jialin Zhang, Qiujie Wang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy
Zhihao Hu, Shuqing Li, Haiqi He, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Utilizing Nanoparticles to Overcome Anti-PD-1/PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy
Yuli Ge, Qiong Zhou, Fan Pan, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 2371-2394
Open Access
Feiyiliu Mixture Promotes Non-small Cell Lung Cancer Cells Apoptosis Via Inhibits ZDHHC18-Mediated AKT1 Phosphorylation
Yuxia Liu, Ding Liang, Shitao Li, et al.
Heliyon (2025), pp. e42780-e42780
Open Access
Research trends and highlights in PD-1/PD-L1 inhibitor immunotherapy in lung cancer: a bibliometric analysis
Zheng Gu, Erle Deng, Jing Ai, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
ABI3BP can inhibit the proliferation, invasion, and epithelial–mesenchymal transition of non-small-cell lung cancer cells
Jian Wu, Xiaokun Yan, Zewen Cheng
Open Life Sciences (2025) Vol. 20, Iss. 1
Open Access
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Page 1 - Next Page

Scroll to top